“I am definitely not interested,” said Dr. Scott Schall, who is an assistant professor of dermatology and dermatology medicine at the University of Pittsburgh Medical Center and has been a practicing dermatologist for nearly a decade.

“I have been told that if I ever decided to start trading stocks, I would go to jail.

I just do not feel like that is the best way to invest.”

Schall has been researching whether it’s possible to become a market maker in the face of growing concerns about the health risks of the drug-resistant MRSA bacteria that has become a major problem.

In 2016, the Centers for Disease Control and Prevention issued a “precautionary statement” warning about the risks of drug-resistance in the MRSA strains that cause the disease.

The drug-producing MRSA strain, Enterococcus faecalis, is resistant to more than half the drugs available in the U.S.

The MRSA infections in the United States have killed about 4,000 people, and the rate of deaths is growing.

A major factor in the increasing number of deaths has been the rise in use of antibiotics that were once thought to be safe, but are now widely used.

The trend of increasing antibiotic use has contributed to the growth of the MRSE.

“I am concerned about what the cost of antibiotic treatment will be if it’s not done,” Schall said.

“How much will the cost be to us as a society when we do not have a cost-effective, affordable treatment for this?

If the costs are not going to be low, we need to do something to address it.”

For some, there’s already an answer.

For years, many medical professionals have been advocating that doctors become market makers, selling their services to patients and then investing their profits back into their own businesses.

But, for Schall and others, the best approach is to stop.

Schall has started to focus more on investing his own money and working out a strategy that will allow him to keep a steady income.

“My goal is to make a lot of money,” he said.

In an interview with Medical News Now, Schall outlined some of the ways he is willing to stop trading stocks and other financial products that he feels are risky.

Here are some of his key points about investing and the dangers of investing in the future:I will not be trading stocks or other financial instruments for at least six months at a time.

For me, that’s my best opportunity, because it’s a very small number of trades per year.

Schall, however, is not opposed to buying shares of companies that are currently trading on the stock market.

He said he will take the time to research a company and make a trade recommendation, and then will take a risk on that trade.

Schill also noted that he doesn’t expect to invest any money in a company if it has not been approved for FDA approval before.

“A lot of times, it is not that we don’t like something or we do have a bad opinion of it, but we are very comfortable with the business and we want to be able to continue with it.

So, that is probably the most effective way,” he told Medical News Live.

Schill is also interested in a range of investments in which he is investing his money.

For example, he would like to invest in some of Google’s business.

He also plans to start a business investing in software.

Schiller’s focus on investing in his own business is also an avenue he’s exploring, because he is concerned about the rise of drug resistance.

“Drug resistance is a problem, and it has become worse in the past two years,” Schiller said.

Schalling said he would also like to work with his students and other health professionals to research and develop treatments for the MRSEA, which is now causing the most deaths.

SchALL said that he and his students are interested in working with a drug-based therapy to prevent MRSA from being passed on to other people.

“If you could get a drug that is actually going to reduce the MR-SA population, it would be worth it,” Schill said.